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Abstract: Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers worldwide and shows a propensity to metastasize
and inﬁltrate adjacent and more distant tissues. HCC is associated
with multiple risk factors, including hepatitis B virus (HBV) infection,
which is especially prevalent in China. Here, we used exome sequenc-
ing to identify somatic mutations in ten HBV-positive individuals
with HCC with portal vein tumor thromboses (PVTTs), intrahepatic
metastases. Both C:G>A:T and T:A>A:T transversions were frequently
found among the 331 non-silent mutations. Notably, ARID1A, which
encodes a component of the SWI/SNF chromatin remodeling com-
plex, was mutated in 14 of 110 (13%) HBV-associated HCC specimens.
We used RNA interference to assess the roles of 91 of the conﬁrmed
mutated genes in cellular survival. The results suggest that seven of
these genes, including VCAM1 and CDK14, may confer growth and
inﬁltration capacity to HCC cells. This study provides a view of the
landscape of somatic mutations that may be implicated in advanced
HCC.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
The molecular changes occurring in cancer are multidimensional.
Besides the standard DNA > RNA > protein sequence of the cen-
tral dogma of molecular biology, there are changes in non-coding
RNA regulation, translational control of protein levels, and post-
translational mechanisms such as acetylation, phosphorylation,
and methylation that can have profound effects on the cellular
signaling processes responsible for carcinogenesis, tumor pro-Journal of Hepatology 20
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have supported the concept of stem cell-like or progenitor sub-
populations that are self-renewing and often less well differenti-
ated and also give rise to the more well differentiated main bulk
of a tumor. These progenitor subpopulations are typically more
resistant to chemotherapy and radiation therapy and are presum-
ably often responsible for tumor recurrence after therapy. Fur-
ther, the clonal nature of tumors and the genetic instability
associated with the carcinogenic process lead to the development
of substantial intratumoral heterogeneity, which then contrib-
utes to additional phenotypes of local invasiveness and metasta-
sis of tumors.
During the last few years, substantial strides have been made
in elucidating the pathogenesis of HCC through technical
advances in molecular characterization and analysis of cell sig-
naling pathways, and also by major advances in DNA sequencing,
in particular next generation sequencing technology (NGS),
which allows whole exome or whole genome characterization
of the tumor genome. Besides conﬁrming alterations of genes
already known to be mutated in cancer, state-of-the-art NGS
methods provide an in-depth view of genetic alteration patterns
occurring in HCC and enable the discovery of previously unchar-
acterized key driver mutations and cellular pathways that are
potentially new targets for HCC treatment [1–5]. Although
important insights into HCC carcinogenesis have been gained
from the NGS studies published over the last 2 years, the genetics
of HCC are still incompletely understood due to the limited num-
ber of HCC samples that have been studied thus far, and the vari-
ety of HCC etiologies which likely contribute to different
pathways of hepatocarcinogenesis [1–5]. The ﬁndings from most
previous NGS studies of HCCs have also been prone to bias
towards the genomes of early stage HCCs, as the tumor tissues
analyzed were mostly obtained from surgical specimens. Genetic
alterations identiﬁed in these samples may therefore be drivers
for HCC initiation but may not contribute to the later stages of
HCC progression and metastasis.
To address this gap, the recent paper by Huang et al. reported
whole exome sequencing results from 10 HBV-infected individu-
als with HCC tumors complicated by portal vein tumor thrombo-
sis (PVTT) (Fig. 1) [6]. Portal vein thrombosis is a manifestation of
advanced stage HCC characterized by macrovascular invasion
into portal vein branches, with extension of the tumors into the
left, right or main portal veins. The genetic alterations found in
the test set of 10 tumors were compared to the alterations in13 vol. 58 j 1042–1044
DNA from 10 pairs of tumors and 
PVTT tissue from HBV-induced HCC
356 non-silent mutations in
347 genes identified
ARID1A mutations were found in 
14 of 110 (13%) HBV-induced HCCs
10 candidate driver genes selected:
TP53, ARID1A, SAMD9L, ARID2, C18orf34,
AMPH, ELMO1, DSE, SPAG17, CSMD3
DNA from additional 85-120 HCC tumors
Non-synonymous mutations in 
PFKFB2, PIK3AP1, KIAA0776, TMEM35, 
IGSF10, HOXA, VCAM1 were identified
7 candidate cancer-associated
 genes identified:
VCAM1, TMEM2, CDK13, HOXA1, 
TMEM35, ELL and CSNK1G3
ARID1A mutations were found in 
2 of 26 HCV-induced HCCs,
1 of 10 non-viral associated HCCs,
1 of 1 HBV/HCV induced HCC
6 candidate non-synonymous ARID1A 
mutations were found 
Mutated ARID1A promoted cell
proliferation, migration and invasion
Downregulation of
 HOXA1, VCAM and TMEM35
was found in 27 (54%), 24 (48%) and 
16 (32%) of 50 HCC samples, respectively
Whole exome sequencing (WES)
- Confirmation by sequencing
- Candidate genes selected
(2 mutations in the same gene 
or mutations in 2 of 10 patients)
Exons of 10 genes were sequenced in
independent set of 100 HCC tumors
Expression levels of
these 7 genes were evaluated
in 50 HCC samples
ARID1A was sequenced in
additional 37 HCC tumors
ARID1A was sequenced in 13 HCC cell lines
The function of ARID1A studied using 
RNAi* in 4 HCC cell lines
Partial protein-coding regions of 147 genes 
adjacent to confirmed mutations from WES were 
sequenced to identify potential driver mutations
91 genes involved in cell proliferation and 
survival were studied in 8 HCC cell lines
RNAi screening*
Fig. 1. Study design, methods, and key ﬁndings from next generation sequencing analyses of HBV-related HCCs. ⁄RNAi screening is a method to study loss of function
of genes by targeting the gene mRNAs using inhibitory RNAs that accelerate mRNA degradation.
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ing in a larger set of 100 samples. Somatic mutations in 347 genes
were identiﬁed in the tumors and/or PVTTs, comprising 331
non-silent single nucleotide variant (SNV) mutations and 25
small insertions and/or deletions. HCC tumors and PVTTs shared
94% of the identiﬁed somatic mutations. Mutated genes identiﬁed
in only PVTTs included KDM6A, CUL9, FDG6, AKAP3, and RNF139
suggesting that these genes may contribute to HCC invasion.
These mutated genes were not identiﬁed in previous NGS studies
of early-stage HCCs induced by HBV or other etiologies [1–5].
The pattern of nucleotide substitutions found in these cancers
also yields clues to their etiology. Strikingly, as compared to the
non-cancerous tissue, the percentage of C:G>A:T transversions
(in which a purine is replaced by a pyrimidine, or viceversa)
and T:A>A:T transversions among the 331 non-silent SNV muta-
tions in the cancerous tissue was signiﬁcantly greater in 5 of 10
(50%) and 4 of 10 (40%) samples, respectively. This substitution
pattern also differed from the pattern found in early-stage
HBV-related HCCs from Japan, in which the dominant pattern
was T:A>C:G transitions (a change in a purine to another purine
nucleotide, or a pyrimidine to another pyrimidine nucleotide) [4].
This raises the intriguing possibility that different mechanisms
regulate tumor mutagenesis at different stages of tumor initia-
tion and progression, but may also reﬂect different environmen-
tal inﬂuences. Aﬂatoxin B1 is a well known genotoxic agent that
induces C:G>A:T transversions, thus it is possible that aﬂatoxin
B1 may have contributed to HCC development in the individuals
in this study [7]. However, it is important to note that the typicalJournal of Hepatology 2013C:G>A:T substitution at codon 249 of TP53, the gene encoding the
tumor suppressor p53, was not found in any of the 10 samples in
this study. Regarding the T:A>A:T transversions, there is no evi-
dence that these are induced by aﬂatoxin B1. This nucleotide sub-
stitution pattern may therefore be due to as yet unidentiﬁed
genotoxic agents; the authors speculate the involvement of the
carcinogen aristolochic acid, found in herbal remedies, or vinyl
chloride, which have both been shown to induce T:A>A:T trans-
versions in other cancer genes [8,9].
Growing evidence from NGS has consistently reported chro-
matin remodeling genes may have an important role as tumor
suppressors in several cancer types, including HCC [2,4,5]. Thus,
these genes could potentially be new targets for HCC treatment.
In this study, multiple mutations in the ARID1A gene, a compo-
nent of the chromatin remodeling pathway, were found in 14
of 110 (13%) HCCs. The prevalence of chromatin remodeling gene
mutations in HCCs varies among the different etiologies of HCCs
and in studies from different geographic regions, ranging from 5%
to 52% (Table 1) [2,4–6].
The authors applied 2 strategies to identify additional driver
gene mutations in HCCs. Protein-coding regions adjacent to the
identiﬁed mutations in 147 genes were sequenced. Additional
non-silent mutations adjacent to conﬁrmed mutations were
identiﬁed in the HOXA1, VCAM1, TMEM35, and PIK3AP1 genes.
Further, a loss-of-function RNAi screen of 91 genes involved in
cell proliferation and survival signaling performed using 8 HCC
cell lines identiﬁed an additional 7 genes which produced
substantial effects on HCC cell phenotypes. These includedvol. 58 j 1042–1044 1043
Table 1. Summary of mutations in chromatin remodeling gene family from recent NGS publications on HCC.
Author, [Ref.] Country ARID1A ARID1B ARID2
HBV HCV NBNC HBV HCV NBNC HBV HCV NBNC
Li et al.,[2] US and Netherlands - - - - - - 0 of 15 
(0%)
6 of 33 
(18%)
2 of 30 
(7%)
China - - - - - - 1 of 35 
(3%)
0 of 10
(0%)
0 of 14 
(0%)
Fujimoto et al., [4] Japan 4 of 11 
(36%)
3 of 14 
(21%)
0 of 2 
(0%)
2 of 11 
(18%)
1 of 14 
(7%)
0 of 2 
(0%)
1 of 11 
(9%)
1 of 14 
(7%)
1 of 2 
(50%)
Guichard et al., [5] France 4 of 35 
(11%)
4 of 24 
(17%)
12 of 66 
(18%)
- - - 2 of 35 
(6%)
1 of 24
 (4%)
4 of 66 
(6%)
Huang et al., [6] China 14 of 110
(13%)
- - - - - 2 of 50 
(4%)
- -
HBV, hepatitis B-related HCC; HCV, hepatitis C-related HCC; NBNC, non-viral hepatitis B/C-related HCC; HCC, hepatocellular carcinoma.
International HepatologyVCAM1 and TMEM2, which were shown to function as inhibitors
of HCC cell proliferation, and CDK14, HOXA1, TMEM35, ELL, and
CSNK1G3, which were shown to enhance HCC cell growth. Again,
these mutated genes were not identiﬁed in the previous NGS
studies.
In summary, this study affords us an in-depth view of the
genetic variations occurring in advanced stages of HBV-induced
HCC, albeit in a limited number of HCCs. As the number and
geographic and clinical diversity of the samples that are analyzed
increases, we will reach a clearer view of the genomic landscape
of HCC. Ongoing multinational efforts through genetic analysis
consortia in the U.S. (The Cancer Genome Atlas Project for
HCC), Europe (HEPTROMIC and MODHEP) and other multina-
tional efforts (International Cancer Genome Consortium) are
ongoing to increase the number of HCC samples analyzed by
NGS and other whole genome approaches. Additional ﬁndings
from these studies should further validate and extend the ﬁnd-
ings reported in this paper.Conﬂict of interest
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